COMPOUNDS FOR STABILIZING RYANODINE RECEPTORS FROM ABERRANT LEVELS OF CALCIUM RELEASE
    7.
    发明公开
    COMPOUNDS FOR STABILIZING RYANODINE RECEPTORS FROM ABERRANT LEVELS OF CALCIUM RELEASE 审中-公开
    VERBINDUNGEN ZUR STABILISIERUNG VON RYANODINREZEPTOREN AUS ABERRANTEN CALCIUMFREISETZUNGSKONZENTRATIONEN

    公开(公告)号:EP2968229A1

    公开(公告)日:2016-01-20

    申请号:EP14763243.4

    申请日:2014-03-14

    Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

    Abstract translation: 本文公开了包含能够使神经元钙异位稳态正常化的化合物的方法和组合物。 还公开了包含这些化合物用于治疗神经元或神经障碍的方法,包括阿尔茨海默氏病,帕金森病,亨廷顿舞蹈病,颞叶性痴呆,皮克病,慢性创伤性脑病,创伤性脑损伤,中风,小脑共济失调,多发性硬化,唐氏综合征 ,以及与老化有关的CNS疾病。

    REGULATION OF CCN2 BY CCN3 AND ITS THERAPEUTIC AND DIAGNOSTIC POTENTIAL IN FIBROSIS, SCLEROSIS AND OTHER DISEASES
    9.
    发明公开
    REGULATION OF CCN2 BY CCN3 AND ITS THERAPEUTIC AND DIAGNOSTIC POTENTIAL IN FIBROSIS, SCLEROSIS AND OTHER DISEASES 有权
    CCN2的调控CCN3及其治疗和诊断潜力囊性纤维化,硬化等疾病

    公开(公告)号:EP1841316A4

    公开(公告)日:2008-07-09

    申请号:EP06717966

    申请日:2006-01-10

    CPC classification number: C07K14/4702 A61K48/00

    Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

Patent Agency Ranking